Bavarian Nordic Reports Impressive Financial Results for the First Half of 2024
COPENHAGEN, Denmark – Bavarian Nordic A/S (OMX: BAVA) has announced its interim financial results and business progress for the first half of 2024. The company has also shared its financial calendar for the year 2025.
Overview of Financial Performance
In the first half of the year, Bavarian Nordic generated a revenue of DKK 2,259 million, with an operating profit (EBITDA) of DKK 441 million. The travel health segment experienced a significant growth of 15%, reaching DKK 1,119 million. Revenue from public preparedness was reported at DKK 1,024 million, meeting the company's expectations. Additionally, other revenue totaled DKK 116 million.
Revenue Highlights
Sales from Rabipur/RabAvert and Encepur surpassed initial acquisition expectations, resulting in a sales milestone of DKK 186 million, which is due to be paid to GSK in the upcoming quarter.
Revised Guidance for 2024
Bavarian Nordic has reaffirmed its updated guidance for the year, projecting total revenues to be approximately DKK 5,300 million and an EBITDA nearing DKK 1,350 million. The revenue from public preparedness included in this guidance is now largely secured through contracts, providing a strong foundation for future sales.
Insights from Leadership
Paul Chaplin, the President & Chief Executive Officer of Bavarian Nordic, reflected on the encouraging developments for the company during the first half of 2024. He pointed out the global concern surrounding mpox, especially with the rising number of cases in Africa, which has led to public health emergency declarations by the African CDC and WHO. Bavarian Nordic is actively working with various stakeholders to ensure equitable access to its mpox vaccine.
Engagement in Global Health
The company has established a strategic partnership with the Africa Centers for Disease Control (CDC) to explore supply opportunities and expand its manufacturing network within Africa. Bavarian Nordic is also collaborating with WHO to navigate regulatory pathways that will facilitate access to vaccines in different countries. This includes seeking approval for adolescent use and conducting clinical trials aimed at children in Africa.
Recent Achievements and Future Orders
Among Bavarian Nordic's recent achievements is a new order for MVA-BN from an undisclosed European country, which is expected to contribute to its 2024 guidance. The company is also planning to boost its vaccine manufacturing capacity to ensure the distribution of 10 million doses by the end of 2025, with the ability to supply up to 2 million doses this year.
Highlights from Recent Months
- Bavarian Nordic launched its mpox vaccine in the U.S. in April, improving access for at-risk populations.
- In April, the company began a rolling BLA submission for its chikungunya vaccine candidate, which was completed in June and accepted by the FDA for priority review in August.
- In April, Bavarian Nordic secured a significant contract valued at EUR 65 million for supplying smallpox vaccines to the rescEU stockpile in 2025.
- Funding from CEPI was allocated in May to support a clinical trial of the mpox vaccine in an African population.
- The company has initiated various applications and notifications concerning regulatory approvals for its vaccines to relevant authorities.
Recent Developments and New Orders
Recent events following the report have further strengthened Bavarian Nordic's operations. Notably, in July, the company converted its existing undrawn DKK 1 billion revolving credit facility into a sustainability-linked loan (SLL). Additionally, it received a positive opinion and recommendations from the EMA for the IMVANEX® vaccine.
Financial Calendar for 2025
Looking forward, Bavarian Nordic has set out its financial calendar for 2025:
- 2024 Annual Report - March 5, 2025
- Annual General Meeting - April 9, 2025
- Three-month report (Q1) - May 9, 2025
- Half-year report (Q2) - August 22, 2025
- Nine-month report (Q3) - November 14, 2025
Contact Information
Contact for Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43
Contact for the US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company dedicated to protecting and saving lives through its innovative vaccines. The company is recognized as a global leader in smallpox and mpox vaccines, supplying governmental bodies to enhance public health preparedness. Bavarian Nordic also boasts a strong portfolio that focuses on vaccines for travelers and endemic diseases.
Frequently Asked Questions
What are the financial highlights of Bavarian Nordic for the first half of 2024?
The company reported revenues of DKK 2,259 million, with an EBITDA of DKK 441 million.
What guidance has Bavarian Nordic provided for 2024?
Bavarian Nordic anticipates approximately DKK 5,300 million in revenue and around DKK 1,350 million in EBITDA for the full year.
How is Bavarian Nordic addressing the mpox crisis?
The company is collaborating with global health organizations to ensure equitable access to its mpox vaccine and ramping up manufacturing capacity.
What significant contracts has Bavarian Nordic secured recently?
Notable contracts include a EUR 65 million award for supplying smallpox vaccines to rescEU and various orders for mpox vaccine supplies.
How can I contact Bavarian Nordic for investor relations?
You can reach Rolf Sass Sørensen at rss@bavarian-nordic.com or call +45 61 77 47 43 for inquiries related to investor relations.
